<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930668</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/024115</org_study_id>
    <nct_id>NCT02930668</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Glucosanol™ in Body Weight Reduction</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled Study to Evaluate Benefit of Glucosanol™ in Reducing Body Weight in Overweight and Moderately Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing&#xD;
      weight in the overweight and obese. The present study aims at expanding the data concerning&#xD;
      the weight management effect of Glucosanol™ in overweight and moderately obese population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mean body weight (kg) after 12 weeks of IP intake in comparison between the verum 500mg study arm and placebo</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.&#xD;
Subjects will take 2 capsules three times a day, 30 mins before meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose (Glucosanol 350mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each capsule contains Glucosanol / Phaselite 350mg&#xD;
Subjects will take 2 capsules three times a day, 30 mins before meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose (Glucosanol 500mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each capsule contains Glucosanol / Phaselite 500mg&#xD;
Subjects will take 2 capsules three times a day, 30 mins before meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucosanol 350mg</intervention_name>
    <arm_group_label>Low dose (Glucosanol 350mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucosanol 500mg</intervention_name>
    <arm_group_label>High dose (Glucosanol 500mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 25 kg/m2 - 34,9 kg/m2&#xD;
&#xD;
          -  Generally in good health• Desire to lose weight&#xD;
&#xD;
          -  Accustomed to regular daily consumption of 3 main meals (breakfast, lunch, dinner)&#xD;
&#xD;
          -  Consistent and stable body weight in the last 3 months prior to V1 (less than 5%&#xD;
             self-reported change)• Readiness to take IP as recommended&#xD;
&#xD;
          -  Readiness to avoid the use of other weight loss and/or management products and/or&#xD;
             programs during the study&#xD;
&#xD;
          -  Readiness to adhere to diet recommendation during the study&#xD;
&#xD;
          -  Readiness to keep the habitual level of physical activity as prior to the study during&#xD;
             the study&#xD;
&#xD;
          -  Readiness and ability to complete the subject diary and study questionnaires&#xD;
&#xD;
          -  Negative pregnancy testing (beta HCG-test in urine) at V1 in women of childbearing&#xD;
             potential&#xD;
&#xD;
          -  Women of childbearing potential: commitment to use contraception methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or hypersensitivity to the components of the investigational products&#xD;
&#xD;
          -  Known allergy or hypersensitivity to members of the Fabaceae family&#xD;
&#xD;
          -  Known food allergy (e.g. to cow's milk, eggs, wheat, crustacean, nuts etc.)&#xD;
&#xD;
          -  Significant disorders:&#xD;
&#xD;
               -  untreated or unstable thyroid gland disorder&#xD;
&#xD;
               -  untreated or unstable hypertension (&gt;140/90 mm Hg)&#xD;
&#xD;
               -  acute or chronic gastrointestinal (GI) disease or malabsorption disorders (e.g.&#xD;
                  inflammatory bowel disease, coeliac disease, pancreatitis etc.)&#xD;
&#xD;
               -  diabetes mellitus- coagulation disorder- any other serious organ or systemic&#xD;
                  diseases that could influence the conduct and/or out-come of the study and/or&#xD;
                  could affect the tolerability of the subject (in the opinion of the investigator)&#xD;
&#xD;
          -  Significant surgery within the last 6 months prior to V1:&#xD;
&#xD;
               -  GI surgery&#xD;
&#xD;
               -  liposuction&#xD;
&#xD;
          -  History of eating disorders like bulimia, anorexia nervosa, binge-eating within the&#xD;
             last 12 monthsprior to V1&#xD;
&#xD;
          -  Clinically relevant excursions of safety laboratoryparameters&#xD;
&#xD;
          -  Any electronic medical implant&#xD;
&#xD;
          -  Regular use of anticoagulants&#xD;
&#xD;
          -  Regular medication and/or supplementation and/or treatment within the last 3 months&#xD;
             prior to V1 and during the study:&#xD;
&#xD;
               -  that could influence body weight (e.g. systemic corticosteroids)&#xD;
&#xD;
               -  that could influence gastrointestinal functions (e.g. antibiotics, laxatives,&#xD;
                  opioids, glucocorticoids, anticholinergics, anti-diarrheals etc.) as per&#xD;
                  investigator judgement&#xD;
&#xD;
               -  for weight management (e.g. fat binder, carbohydrate/starch blocker, fat burner,&#xD;
                  satiety products, acupuncture etc.)&#xD;
&#xD;
          -  Consumption of food supplements or natural health products for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Diet to lose and/or manage weight (except ac-cording to the study protocol)&#xD;
&#xD;
          -  Vegetarian, vegan or macrobiotic diet&#xD;
&#xD;
          -  Smoking cessation within 6 months prior to V1 or during the study (regular smoking&#xD;
             during the study at the same level as prior to the study is allowed)&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  History of or current abuse of drugs, alcohol or medication&#xD;
&#xD;
          -  Inability to comply with study requirements&#xD;
&#xD;
          -  Subjects who are deprived of their freedom by administrative or legal decision or who&#xD;
             are in guardianship&#xD;
&#xD;
          -  Participation in another clinical study in the 30 days prior to V1 and during the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

